Disease area
Hematologic malignancies
Multiple myeloma
B-cell malignancies
Myeloid malignancies
Classical hematology
Showing 3 recruiting clinical trials
Untreated CLL/SLL
TAILOR
Phase
NCT05963074
Compound
Ibrutinib (BTK inhibitor) ± venetoclax
Relapsed or refractory
B-cell NHL
B-cell NHL
95566692LYM1001
Phase
NCT07308132
Compound
JNJ-95566692 (CD79b × CD20 × CD3 trispecific Ab) ± JNJ-87801493 (CD20 × CD28 bispecific Ab)
Relapsed or refractory AML, high-risk MDS, or CLL/SLL
95804306EDI1001
Phase
NCT07572006
Compound
JNJ-95804306 ± SOC
The safety and efficacy of the investigational use of these products have not been determined.
There is no guarantee that the investigational uses listed will be filed with and/or approved for marketing by any regulatory agency.
Ab, antibody; AML, acute myeloid leukemia; BCL-2, B-cell lymphoma 2 protein; BTK, Bruton’s tyrosine kinase; CD, cluster of differentiation; CLL, chronic lymphocytic leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; SLL, small lymphocytic lymphoma; SOC, standard of care.